Skip to main content
. 2018 Jun 6;36(21):2231–2240. doi: 10.1200/JCO.2017.76.4647

Fig 2.

Fig 2.

National Cancer Institute–Pediatric MATCH (Molecular Analysis for Therapeutic Choice) trial schema. CR, complete response; FGFR, fibroblast growth factor receptor; mTOR, mechanistic target of rapamycin; PARP, polyadenosine diphosphate-ribose polymerase; PD, progressive disease; PI3K, phosphatidylinositol 3-kinase; PR, partial response; SD, stable disease. Reprinted with permission.17